Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs

  • Technology appraisal guidance
  • TA803
  • Published: 

History

Documents created during the development process.

Expected publication

Final draft guidance

Notes

Invitation to participate

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators